Prognostic role of miR-221 and miR-222 expression in cancer patients

• Verfasst von: Ravegnini, Gloria [VerfasserIn]
• Verfasst von: Lorenzo Bermejo, Justo [VerfasserIn]
• Verfasst von: Hrelia, Patrizia [VerfasserIn]
• Verfasst von: Terrazzino, Salvatore [VerfasserIn]
• Verfasst von: Angelini, Sabrina [VerfasserIn]
• Titel: Prognostic role of miR-221 and miR-222 expression in cancer patients
• Titelzusatz: a systematic review and meta-analysis
• Verf.angabe: Gloria Ravegnini, Sarah Cargnin, Giulia Sammarini, Federica Zanotti, Justo Lorenzo Bermejo, Patrizia Hrelia, Salvatore Terrazzino and Sabrina Angelini
• E-Jahr: 2019
• Jahr: 11 July 2019
• Umfang: 24 S.
• Fussnoten: Gesehen am 04.11.2019
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2019
• Band/Heft Quelle: 11(2019,7) Artikel-Nummer 970, 24 Seiten
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers11070970
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cancer
• Sach-SW: miR-221
• Sach-SW: miR-222
• Sach-SW: overall survival
• Sach-SW: progression-free survival
• K10plus-PPN: 1680890921

Abstract

Background: A wealth of evidence has shown that microRNAs (miRNAs) can modulate specific genes, increasing our knowledge on the fine-tuning regulation of protein expression. miR-221 and miR-222 have been frequently identified as deregulated across different cancer types; however, their prognostic significance in cancer remains controversial. In view of these considerations, we performed an updated systematic review and meta-analysis of published data investigating the effects of miR-221/222 on overall survival (OS) and other secondary outcomes among cancer patients. A systematic search of PubMed, Web of Knowledge, and Cochrane Library databases was performed. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the strength of association. Results: Fifty studies, analyzing 6086 patients, were included in the systematic review. Twenty-five studies for miR-221 and 17 studies for miR-222 which assessed OS were included in the meta-analysis. High expression of miR-221 and miR-222 significantly predicted poor OS (HR: 1.48, 95% CI: 1.14&ndash;1.93, p = 0.003 and HR: 1.90, 95% CI: 1.43&ndash;2.54, p < 0.001, respectively). Subgroup analysis revealed that the finding on miR-221 was not as robust as the one on miR-222. Furthermore, high miR-222 expression was also associated with worse progression-free survival and disease-free survival pooled with recurrence-free survival. Conclusions: The meta-analysis demonstrated that high expression of miR-222 is associated with poor prognosis in cancer patients, whereas the significance of miR-221 remains unclear. More work is required to fully elucidate the role of miR-221 and miR-222 in cancer prognosis, particularly in view of the limitations of existing results, including the significant heterogeneity and limited number of studies for some cancers.